Brief: Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies
10/01/2025 13:11
Jan 10 (Reuters) - Palvella Therapeutics Inc PVLA.O :
* PALVELLA THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS
FROM
PHASE 2 CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL
(QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC
MALFORMATIONS IN THE JOURNAL OF VASCULAR ANOMALIES
* PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN
RAPAMYCIN
FOR MICROCYSTIC LMS WITH DATA EXPECTED Q1 2026
* PALVELLA THERAPEUTICS INC - QTORIN RAPAMYCIN
WELL-TOLERATED WITH
NO SERIOUS ADVERSE EVENTS
* PALVELLA THERAPEUTICS INC - 100% PARTICIPANTS SHOW
IMPROVEMENT
AFTER 12 WEEKS OF QTORIN RAPAMYCIN
Source text: urn:newsml:reuters.com:*:nGNXmRDSd
Further company coverage: PVLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs